Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 09, 2017 11:22:19 AM
BTW: It will take some years, say 2 to 4, before aldoxorubicin, if approved, will generate hefty royalty income. Replacing single use doxorubicin is not enough, not even in STS. Probably neither is replacement of dox plus IFOS combo with aldox plus IFOS. Aldox needs to replace dox in combinations with new SOC drugs like olaratumab (in STS) and that to happen will likely take a small trial ( < 100 subjects) per combo. Just to confirm that there is no nasty surprises after the switch. It follows that wider use of aldox will emerge some years after the first approval.
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM